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Abstract
Purpose—Prescription drug overdose (PDO) deaths are a critical public health problem in the 
United States. This study aims to assess the association between emergency department (ED) 
utilization patterns in a cohort of ED patients and the risk of subsequent unintentional PDO 
mortality.
Methods—Using data from the New York Statewide Planning and Research Cooperative System 
for 2006–2010, a nested case-control design was used to examine the relationship between ED 
utilization patterns in New York State residents of age 18–64 years and subsequent PDO death.
Results—The study sample consisted of 2732 case patients who died of PDO and 2732 control 
ED patients who were selected through incidence density sampling. With adjustment for 
demographic characteristics, and diagnoses of pain, substance abuse, and psychiatric disorders, the 
estimated odds ratios of PDO death relative to one ED visit or less in the previous year were 4.90 
(95% confidence interval [CI]: 4.50–5.34) for those with two ED visits, 16.61 (95% CI: 14.72–
18.75) for those with three ED visits, and 48.24 (95% CI: 43.23–53.83) for those with four ED 
visits or more.
Conclusions—Frequency of ED visits is strongly associated with the risk of subsequent PDO 
death. Intervention programs targeting frequent ED users are warranted to reduce PDO mortality.
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Increases in drug overdose death in the United States are a critical public health problem. 
Nearly 60% of drug overdose deaths involved prescription drugs, and in 2011, 1.4 million 
emergency department (ED) visits involved nonmedical use of prescription drugs [1,2]. 
Frequent ED utilization has been shown to be a marker for substance use—narcotic use, 
especially [3,4], and is associated with nonmedical opioid use, drug diversion, and poorly 
controlled pain [3–5]. Therefore, frequent ED utilization may be a marker for increased risk 
for prescription drug overdose (PDO), and this point of clinician contact may serve as a 
setting to launch preventive intervention efforts [6–15]. Preventive interventions targeted at 
ED patients at high risk for PDO death, may include advice such as not mixing opioids with 
sedatives or alcohol [16], or targeted patient education initiatives [17]. Furthermore, 
identifying high risk populations can help medical practitioners decide whom to target with 
screening, intervention (e.g., take-home naloxone), and treatment program referrals [18–24].
Despite the importance of the ED as a key clinical entry point for patients at high risk of 
PDO, the relationship between ED utilization patterns and subsequent drug overdose death 
is understudied. In the present study, we used a nested case-control design to examine the 
relationship between ED utilization in a cohort of ED patients and the risk of subsequent 
unintentional PDO death. Characterizing risk markers for fatal PDO available in 
administrative databases can be useful for identifying individuals at increased likelihood of 
PDO death. The goal of the analysis was to determine whether increased ED utilization in a 
cohort of ED patients was associated with subsequent unintentional PDO death.
Materials and methods
Data sources
Data for this study came from the New York Statewide Planning and Research Cooperative 
System (SPARCS) for the years 2006–2010. SPARCS is a data reporting system that 
collects ED visit data from nonfederal hospitals in New York State (NYS) [25]. SPARCS 
contains patient-level data including patient characteristics, discharge diagnoses, procedures 
received, and charges for ED visits [25]. To ensure data quality, SPARCS visit data are 
examined for proper formatting upon submission format [26]. Data completeness and 
accuracy are assessed for each facility. Data are reviewed monthly and compared with other 
benchmarks from Department of Health data [26,27]. To ascertain dates of death, and 
underlying and contributing causes of death for patients who visited the ED during the study 
period, SPARCS ED data were linked to NYS and New York City vital statistics records by 
a SPARCS analyst. Data were linked based on the patient’s date of birth, residential address, 
first two characters of the patient’s first name, the first and last two characters of the 
patient’s last name, and the last four digits of the patient’s social security number. PDO 
mortality within one year of the most recent ED visit within the study period 2006–2010 was 
evaluated. The study protocol was reviewed and approved by the Institutional Review Board 
of Columbia University Medical Center (IRB-AAAK6304 New York, NY).
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ED utilization (1, 2, 3, and ≥4 visits) in last year of follow-up was calculated with respect to 
date of death for cases. The choice of these time frames was based on research by the 
Agency for Healthcare Research and Quality, which proposed two ED visits or more in 3 
days, three ED visits or more in 90 days, and four ED visits or more in a year as metrics to 
track suboptimal quality of care [28].
Model evaluation for which ED utilization time frame best fit the data was based on Akaike 
information criterion statistics [29]. Time-varying 365-day ED utilization was 
operationalized using three separate indicator variables: two, three, or four or more ED visits 
in a 365-day time window. When calculating these ED utilization measures, admissions for 
patients who were transferred on the day of discharge to other acute care hospitals, including 
patients admitted to hospital specialty units, inpatient rehabilitation facilities, skilled nursing 
facilities, and long-term care hospitals, were collapsed and treated as one continuous 
admission. If a patient died at the ED, this visit was not counted. Same-day ED revisits were 
included in the analyses.
Other risk markers
Other risk markers that were evaluated included age, sex, and race (white, black, Asian/
Pacific Islander/Native American, and other). To help improve model fit, a discharge against 
medical advice (AMA) at the initial ED visit and several other diagnoses were examined as 
potential risk markers for drug overdose death given that discharges AMA are associated 
with drug abuse [30]. Previous studies have noted a rise in nontraumatic dental condition-
related ED visits that may result in an opioid analgesic prescription (Online Appendix A) 
[31–33]. Studies of drug overdose have noted that substance use disorders, mental health 
disorders, and chronic pain conditions are associated with drug overdose [34–42]. 
Accordingly, these conditions were evaluated as potential risk markers of PDO death. In 
accordance with the State Personal Privacy Protection Law, individual characteristics 
involving less than six patients may not be reported.
Outcome measurements
Classification codes from the International Classification of Diseases and Related Health 
Problems, 10th Revision were used to classify PDO deaths. Unintentional and undetermined 
intent overdose deaths (X40–X44, Y10–Y14), where there was also an indication that a 
prescription drug was a contributing cause of death (T40.2, T40.3, T40.4 [opioid 
analgesics], T40.6 [Other and unspecified narcotics], T42.2 [Succinimides and 
oxazolidinediones], T42.3 [Barbiturates], T42.4 [Benzodiazepines], T43.0 [Tricyclic and 
tetracyclic antidepressants], T43.1 [Monoamine-oxidase-inhibitor antidepressants], T43.2 
[other and unspecified antidepressants], T50.9 [other and unspecified drugs]), were 
evaluated as the primary outcome of interest [43,44].
Study design
A nested case-control study design was used. ED patients who subsequently died of PDO 
during the follow-up were considered cases. Using incidence density sampling, one control 
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was randomly selected from the same base population from which the cases arose and was 
matched to the corresponding case on follow-up time [45]. The first visit date in the study 
period was considered the entry visit. The end of follow-up for cases was the date when 
PDO death occurred. For controls, the end of follow-up time corresponded to elapsed time 
from study entry to the time when death occurred for the matched case. To be eligible to be 
a control the individual must be alive when the case occurred. All case patients were able to 
be matched with control patients. Incidence density sampling was used because ED 
utilization is time-varying. Time-dependent covariates may be accurately assessed in nested 
case-control study by using incidence density-based sampling to create risk sets [45].
The cohort from which the cases arose included patients who were NYS residents, were 18–
64 years of age, and who visited the ED in NYS from 2006–2010 (Fig. 1). Patients with any 
discharge diagnoses indicating palliative care, cancer, metastatic carcinoma, or sickle cell 
anemia at any ED visit were excluded from the cohort because they may have different ED 
utilization patterns and may receive higher doses of opioids than other patients. Patients 
without a previous ED visit who died during the index ED visit were excluded from the 
cohort because there was no pattern of prior ED visits to predict the study outcome. Of the 
remaining patients who visited the ED, all individuals who subsequently died of a PDO 
death were used as cases.
Statistical analysis
To better understand the attributes of the individuals included in this study, the frequency 
distribution of patient characteristics at the initial ED visit from 2006–2010 who 
subsequently died of a PDO was compared with those of patients who did not. Differences 
between groups were compared using χ2 tests. A P-value of .05 or less was considered 
statistically significant. Baseline characteristics were examined in unadjusted models to 
estimate the odds ratio (OR) and 95% confidence interval (CI) for PDO death. Conditional 
logistic regression was used to estimate ORs [46,47]. Because this study is based on the 
nested case-control design, the measure of association is the OR. With incidence density 
sampling, the OR approximates the incidence rate ratio [48]. To prevent over-adjustment in 
multivariable models, demographic characteristics (age, sex, and composite independent 
variables of diagnoses at study entry) were created and included in the final multivariable 
model. Four binary composite independent variables of diagnoses at entry were created, 
including presence or absence of the following: (1) Diagnosis of alcohol abuse, alcohol drug 
seeking, drug dependence, opioid abuse, other drug abuse, nonfatal opioid overdose, or 
sedative anxiolytic abuse at the initial ED visit; (2) Diagnosis of anxiety disorder, 
depression, episodic mood disorder, major depressive disorder, personality disorder, post-
traumatic stress disorder, psychosis or agitation, or schizophrenia at their initial ED visit; (3) 
Diagnosis of back pain, fibromyalgia, or musculoskeletal pain at their initial ED visit; (4) 
Diagnosis of general symptoms, soft tissue disorders, nontraumatic dental conditions, or 
vertebrae disorders at their initial ED visit. The multivariable models included the following 
independent variables: time independent age at study entry, sex, race, AMA status, 
composite independent variables of diagnoses at study entry, and time-varying ED 
utilization. Analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
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A total of 2732 PDO deaths were recorded during the follow-up and were used as cases in 
this study (Fig. 1). Characteristics of cases and controls at study entry showed that patients 
who subsequently died of a PDO were disproportionately 35–54 years of age (59.1% vs. 
42.2%, χ2 = 170.5, P < .0001), male (65.2% vs. 44.2%, χ2 = 243.3, P <.0001), and identified 
as white race (74.4% vs. 51.6%, χ2 = 319.3, P <.0001) compared with patients that did not 
die of PDO (Table 1). Additionally, patients who subsequently died of a PDO were more 
likely to be discharged AMA at the initial visit (3.9% vs. 2.1%, χ2 = 15.2, P < .0001, Table 
1) than those that did not die. In unadjusted models, patients who were discharged AMA at 
the initial ED visit were more likely to subsequently die of PDO (Table 2) than patients were 
not discharged AMA. Having a psychiatric disorder diagnosis, or any substance abuse, or 
dependence diagnosis was also associated with increased risk of PDO death (Table 2).
Multivariable models adjusted for age, race, and sex show that drug, or alcohol abuse, or 
dependence diagnoses at an initial ED visit were associated with five times greater risk of 
PDO death (adjusted odds ratio [aOR]: 5.40, 95% CI: 4.84–6.03, Table 3). Having a 
psychiatric disorder diagnosis at the initial ED visit was associated with a three times higher 
risk of subsequent PDO death compared with patients without a psychiatric disorder 
diagnoses at the initial ED visit (aOR: 3.71, 95% CI: 3.23–4.14). Having a pain-related 
diagnosis at the initial ED visit was associated with a 73% higher risk of PDO death (aOR: 
1.88, 95% CI: 1.60–1.86). Other diagnoses, including general symptoms, soft tissue, 
nontraumatic dental, or vertebrae disorders at an initial ED visit were associated with 40% 
higher risk of PDO death (aOR 1.38, 95% CI 1.28–1.63). A discharge AMA at the initial 
visit was also associated with subsequent PDO death (aOR: 1.38, 95% CI: 1.16–1.58).
At the end of follow-up, about 50% of the cases and 15% of the controls had two or more 
visits in the prior year. Relative to one or less visit in the previous year, the aORs of PDO 
death were 4.90 (95% CI: 4.50–5.34) for those with two visits, 16.61 (95% CI: 14.72–18.75) 
for those with three visits, and 48.24 (95% CI: 43.23–53.83) for those with four or more 
visits (Table 3).
Discussion
This study is among one of the first studies to evaluate the relationship between patterns of 
ED utilization and PDO death, as opposed to the more well-defined literature on “doctor 
shopping,” the practice of visiting multiple health care providers to obtain controlled 
substances [49–53]. ED utilization patterns are thought to be related to poorly controlled 
pain and in some instances substance use [3,54,55]. This study indicates that ED utilization 
patterns are also important predictors of PDO death.
ED visits are common among people who abuse drugs and alcohol [6,56–58]. An alcohol 
intervention trial of college students found that 30% of men and 27% women visited the ED 
at least once in the 2 years of follow-up [6]. Another study of adolescents using ED at the 
University of Michigan Medical Center found that 35% of past-year self-reported 
nonmedical prescription opioid users had an ED visit in the prior year, compared with 25% 
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of respondents not reporting past-year nonmedical prescription opioid users [58]. Compared 
with individuals not reporting past-year nonmedical sedative use, self-reported past-year 
nonmedical sedative users were more likely to have had an ED visit in the past year (25% 
vs. 40%) [58].
Additionally, this investigation demonstrates that patients who were discharged AMA were 
more likely to die of PDO death than patients who were not discharged AMA; previous 
literature has shown that leaving AMA is associated with substance use [30]. Although it is 
generally believed that drug-seeking patients have increased ED utilization and that patients 
discharged AMA are more likely to abuse drugs and alcohol, examination of ED utilization 
patterns with respect to overdose is scant [30,54,55].
This study confirms prior findings that patients who are male, ages 35–54 years, and are 
identified as white race are at increased risk for PDO compared with females, other age 
groups, and races [34,39,40,43,52,59–63], and it mirrors previous research on the 
association of clinical risk markers for overdose, such as psychiatric comorbidities, drug and 
alcohol abuse, previous ED visits for opioid overdose and chronic pain conditions [34–
36,39,40,64]. Of note, at study entry, chronic pain and other conditions, such as visceral pain 
and headaches, which previous studies have found to be frequently occurring in patients 
who overdose [36,55], were more frequently noted for patients who did not subsequently die 
of PDO.
ED visits may serve as an opportunity to launch a preventive intervention, as to date 
findings suggest that prescription drug monitoring programs have had limited or mixed 
effects on reducing drug overdose deaths and opioid or other controlled substance 
prescribing [65–69]. Risk assessment and stratification can help identify patients most 
vulnerable to overdose who are using ED services [40,62]. Based on all 2006–2010 
SPARCS ED data, about 40% of patients who subsequently die of overdose, who were 18–
64 years, and NYS residents had multiple ED encounters (data not shown). About 19% of 
people who died of PDO did not visit the ED during the study period (data not shown).
These repeated visits represent opportunities to intervene, such as referral to substance abuse 
treatment, or access to rescue treatments, including take-home naloxone for reversing opioid 
overdose. A Canadian study found that by monitoring frequent ED users, it was possible to 
reduce ED visits and improve patient care by using medical and social interventions, such as 
denying narcotic and benzodiazepine prescriptions, restricting patients to using one 
pharmacy, providing supportive counseling, and linking patients with community mental 
health services [70]. Although there is debate regarding the appropriateness of interventions 
in already overburdened EDs, reports show that individuals with four ED visits or more in a 
year make up 28% of all ED visits [28], suggesting interventions targeted at high ED 
utilizers adequate care outside the ED may help alleviate strain on EDs.
Limitations
This study has several notable limitations. First, this study examines whether ED utilization 
patterns can predict overdose death. Preventive interventions launched in the ED will not 
directly affect drug user populations who do not use ED services, and only 40% of all 
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overdose victims 18–64 years of age in NYS had multiple ED visits. If patients who died at 
their only ED visit had been included, effect estimates would have been slightly attenuated. 
Second, increased health care utilization is a marker of illness and sicker patients who are 
more likely to receive more pharmacologic treatments and are at increased risk for all-cause 
mortality. Third, this investigation is based on currently coded diagnoses and not necessarily 
conditions present in individuals; some conditions may not be recorded in administrative 
data. It is likely that only the most severe comorbidities of patients are recorded, and that the 
findings of this study may not be generalizable to patients with less severe disease. Fourth, 
this study does not evaluate provider prescribing or its appropriateness. Because SPARCS 
does not collect prescription drug data, it is not possible to determine if patients were 
prescribed prescription opioids or other drugs at their ED visit. Similarly, other important 
characteristics cannot be accounted for such as, drugs taken, drug dosages, the setting in 
which drugs were taken or the mode of drug administration (e.g., oral or intravenous), 
factors associated with opioid adverse events, and overdose death [39,60,62,71–73]. Fifth, 
there have been conflicting studies regarding the accuracy of drug overdose death 
certification and coding [74–77]. If drug overdose deaths are not ascertained and 
indiscriminately not recorded on death certificates, this study may underestimate effect 
estimates. Additionally, if a death to a NYS resident occurred out of state, the death would 
not be captured in this analysis.
Conclusions
ED utilization patterns are a strong predictor of subsequent overdose death. Understanding 
the timing of overdose death in relation to ED utilization is essential to recognizing which 
patients to target with overdose prevention interventions. Identifying markers for increased 
risk is paramount for optimizing the effectiveness of preventive intervention efforts, such as 
providing high-risk patients, their friends and families with take-home naloxone, or drug 
treatment referral. Future studies should focus on identifying other health encounter patterns 
and alternative approaches to aid vulnerable individuals who do not use ED services.
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Table 1
ED utilization and demographic and clinical characteristics by case-control status, SPARCS emergency 
department data, New York State, 2006–2010
Characteristics* Cases Controls
No. % No. %
ED visits in the last year of follow-up
  ≤1 1388 50.8 2312 84.6
  2 464 17.0 244 8.9
  3 278 10.2 81 3.0
  ≥4 602 22.0 95 3.5
Demographics
  Age† (y)
    18–24 351 12.9 592 21.7
    25–34 541 19.8 655 24.0
    35–44 796 29.1 596 21.8
    45–54 818 29.9 558 20.4
    55–64 226 8.3 331 12.1
  Sex†
    Female 951 34.8 1525 55.8
    Male 1781 65.2 1207 44.2
  Race†
    White 2033 74.4 1410 51.6
    Black or African American 313 11.5 679 24.9
    Native American/Asian/Pacific Islander 26 1.0 76 2.8
    Other or unknown 360 13.2 567 20.8
Clinical characteristics
  Discharged AMA†
    Yes 106 3.9 57 2.1
    No 2626 96.1 2675 97.9
  Psychiatric diagnosis
    Anxiety disorder†
     Yes 125 4.6 51 1.9
     No 2607 95.4 2681 98.1
    Depression†
     Yes 125 4.6 35 1.3
     No 2607 95.4 2697 98.7
    Episodic mood disorder†
     Yes 100 3.7 25 0.9
     No 2632 96.3 2707 99.1
    Major depressive disorder













Brady et al. Page 14
Characteristics* Cases Controls
No. % No. %
     Yes 18 0.7 11 0.4
     No 2714 99.3 2721 99.6
    Personality disorder†
     Yes 107 3.9 26 1.0
     No 2625 96.1 2706 99.1
    Psychosis or agitation†
     Yes 95 3.5 12 0.4
     No 2637 96.5 2720 99.6
    Schizophrenia†
     Yes 42 1.5 7 0.3
     No 2690 98.5 2725 99.7
  Substance use diagnosis
    Alcohol abuse†
     Yes 215 7.9 68 2.5
     No 2517 92.1 2664 97.5
    Alcohol drug seeking†
     Yes 486 17.8 97 3.6
     No 2246 82.2 2635 96.4
    Drug dependence†
     Yes 125 4.6 13 0.5
     No 2607 95.4 2719 99.5
    Opioid abuse†
     Yes 48 1.8 7 0.3
     No 2684 98.2 2725 99.7
    Other drug abuse†
     Yes 137 5.0 12 0.4
     No 2595 95.0 2720 99.6
    Tobacco use disorder†
     Yes 104 3.8 69 2.5
     No 2628 96.2 2663 97.5
  Pain-related diagnosis
    Arthritis
     Yes 99 3.6 88 3.2
     No 2633 96.4 2644 96.8
    Back pain†
     Yes 244 8.9 134 4.9
     No 2488 91.1 2598 95.1
    Fibromyalgia
     Yes 30 1.1 26 1.0
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Characteristics* Cases Controls
No. % No. %
     No 2702 98.9 2706 99.1
    Headaches
     Yes 73 2.7 92 3.4
     No 2659 97.3 2640 96.6
    Joint disorder
     Yes 78 2.9 69 2.5
     No 2654 97.1 2663 97.5
    Musculoskeletal pain
     Yes 306 11.2 301 11.0
     No 2426 88.8 2431 89.0
    Neuropathy
     Yes 8 0.3 10 0.4
     No 2724 99.7 2722 99.6
    Visceral pain†
     Yes 24 0.9 66 2.4
     No 2708 99.1 2666 97.6
  Other conditions
    Abdominal symptoms†
     Yes 132 4.8 170 6.2
     No 2600 95.2 2562 93.8
    General symptoms†
     Yes 189 6.9 146 5.3
      No 2543 93.1 2586 94.7
    Nontraumatic dental
     Yes 65 2.4 65 2.4
     No 2667 97.6 2667 97.6
    Respiratory symptoms†
     Yes 135 4.9 204 7.5
     No 2597 95.1 2528 92.5
    Soft tissue disorder
     Yes 94 3.4 79 2.9
     No 2638 96.6 2653 97.1
*
Data for prior nonfatal opioid overdose, sedative abuse, post-traumatic stress disorder, central sleep apnea, vertebrae disorders not shown because 
cell counts less than 6.
†
P < 0.05.
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Table 2
Unadjusted ORs and 95% CIs for risk of PDO death by ED utilization and demographic and clinical 
characteristics from nested case-control analysis, SPARCS ED data, New York State, 2006–2010
Characteristics OR (95% CI)
ED visits in the past year
  ≤1
  2 3.2 (2.7–3.7)
  3 5.7 (4.4–7.4)
  ≥4 10.6 (8.4–13.2)
Demographics
  Age (y)
    18–24 0.63 (0.60–0.67)
    25–34 1.00
    35–44 2.26 (2.15–2.37)
    45–54 1.74 (1.65–1.83)
    55–64 0.69 (0.65–0.74)
  Sex
    Female 1.00
    Male 2.01 (1.94–2.08)
  Race
    White 1.00
    Black or African American 0.29 (0.27–0.30)
    Native American/Asian/Pacific Islander 0.27 (0.23–0.31)
    Other or unknown 0.47 (0.45–0.50)
Clinical characteristics
  Discharged AMA 2.89 (2.74–3.04)
  Psychiatric diagnoses
    Anxiety disorder 4.16 (3.72–4.64)
    Depression 2.82 (2.54–3.14)
    Episodic mood disorder 4.27 (3.70–4.91)
    Major depressive disorder 1.60 (1.26–2.04)
    Personality disorder 4.76 (2.8–8.04)
    Post-traumatic stress disorder 2.91 (1.81–4.67)
    Psychosis or agitation 7.25 (5.99–8.78)
    Schizophrenia 5.18 (4.07–6.59)
  Substance use diagnoses
    Alcohol abuse 3.23 (2.96–3.51)
    Alcohol drug seeking 5.03 (4.68–5.39)
    Drug dependence 8.63 (7.16–10.41)
    Opioid abuse 13.71 (10.13–18.55)
    Other drug abuse 6.81 (5.86–7.93)
    Prior nonfatal opioid overdose 13.40 (7.93–22.64)
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Characteristics OR (95% CI)
    Sedative anxiolytic abuse 8.57 (5.02–14.61)
    Tobacco use disorder 1.46 (1.33–1.61)
  Pain-related diagnoses
    Arthritis 1.02 (0.94–1.12)
    Back pain 2.20 (2.06–2.35)
    Fibromyalgia 1.34 (1.10–1.62)
    Headaches 0.98 (0.89–1.07)
    Joint disorder 1.09 (0.99–1.22)
    Musculoskeletal pain 1.15 (1.09–1.21)
    Neuropathy 0.64 (0.48–0.86)
    Visceral pain 0.39 (0.33–0.45)
  Other conditions
    Abdominal symptoms 0.89 (0.83–0.95)
    Central sleep apnea 0.18 (0.05–0.60)
    General symptoms 1.09 (1.02–1.17)
    Nontraumatic dental 1.13 (1.02–1.26)
    Respiratory symptoms 0.72 (0.67–0.77)
    Soft tissue disorder 1.38 (1.25–1.51)
    Vertebrae disorders 2.22 (1.78–2.78)
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Table 3
Adjusted ORs and 95% CIs for risk of PDO death by ED utilization, demographic and clinical characteristics, 
SPARCS ED data, New York State, 2006–2010
Characteristic OR (95% CI)
ED visits in the past year
  2 4.90 (4.50–5.34)
  3 16.61 (14.72–18.75)
  ≥4 48.24 (43.23–53.83)
Age, y
  18–24 0.49 (0.44–0.54)
  35–44 1.86 (1.71–2.01)
  45–54 1.74 (1.60–1.90)
  55–64 0.82 (0.74–0.92)
Race
  Black or African American 0.27 (0.25–0.29)
  Native American/Asian/Pacific Islander 0.27 (0.21–0.34)
  Other or Unknown 0.42 (0.39–0.45)
Sex
  Male 2.35 (2.22–2.50)
Discharged AMA at initial ED visit 1.38 (1.16–1.63)
Drug or alcohol abuse, or dependence diagnosis 5.40 (4.84–6.03)
Mental health diagnosis 3.71 (3.23–4.14)
Pain-related diagnosis 1.73 (1.60–1.86)
Other diagnosis 1.38 (1.26–1.50)
Ann Epidemiol. Author manuscript; available in PMC 2016 August 01.
